MLA 0.00% 8.5¢ medical australia limited

Ann: MLA Quarterly Update March 2017, page-3

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 96 Posts.
    Agree Spartacus.

    It’s really pleasing to see Tuta growing strongly again at a rate of 9.6%. It will need to keep growing like this if the company is to offset the loss of CareFusion in FY2018.

    The Tuta business achieving the same sales as the December quarter is noteworthy and a fantastic achievement. Traditionally December is strong as hospitals order up ahead of the break with January being very weak.

    There is a lot of potential with Clements, but it remains a WIP.

    In rough terms Tuta accounts for 70% of MLA sales and Clements 10% - i.e. Tuta dominates the sales. These two companies have a long history and it’s interesting to note that once upon a time this was somewhat reversed. At its peak Clements did $60M in sales per annum and Tuta did $30M per annum.

    We can only dream of such sales figures like these now!

    References
    Clements sales: http://adb.anu.edu.au/biography/clements-hubert-ingham-12846
    Tata sales: http://www.medaust.com/irm/PDF/1036_0/ResultsofGeneralMeeting   (section 2.2)
 
watchlist Created with Sketch. Add MLA (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.